References

How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

10.1038/jid.2009.391 · 2010 · External reference

Oral Treatment of Pustulosis Palmo‐Plantaris With a New Retinoid, Ro 10‐9359

1979 · External reference

Scoring and Monitoring the Severity of Psoriasis. What Is the Preferred Method? What Is the Ideal Method? Is PASI Passé? Facts and Controversies

10.1016/j.clindermatol.2009.03.001 · 2010 · External reference

Randomized Clinical Trials for Psoriasis 1977‐2000: The EDEN Survey

10.1046/j.1523-1747.2003.12145.x · 2003 · External reference

What Are the Best Outcome Measures for Assessing Plaque Psoriasis Severity? A Systematic Review of the Literature

10.1111/j.1468-3083.2009.03562.x · 2010 · External reference

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice

10.1016/j.jid.2018.01.041 · 2018 · External reference

An Updated Survey for the 2007–2013 Period of Randomized Controlled Trials for Psoriasis: Treatment Modalities, Study Designs, Comparators, Outcome Measures and Sponsorship

10.1111/jdv.13089 · 2015 · External reference

A Simplified Psoriasis Area Severity Index (SPASI) for Rating Psoriasis Severity in Clinic Patients

10.5070/d318w9j736 · 2004 · External reference

Product of the Physician Global Assessment and Body Surface Area: A Simple Static Measure of Psoriasis Severity in a Longitudinal Cohort

10.1016/j.jaad.2013.07.040 · 2013 · External reference

PGA×BSA: A Measure of Psoriasis Severity Tested in Patients With Active Psoriatic Arthritis and Treated With Certolizumab Pegol

10.3899/jrheum.170244 · 2018 · External reference

The Physician Global Assessment and Body Surface Area Composite Tool Is a Simple Alternative to the Psoriasis Area and Severity Index for Assessment of Psoriasis: Post Hoc Analysis From PRISTINE and PRESTA

10.2147/ptt.s169333 · 2018 · External reference

Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results From ESTEEM 1 and ESTEEM 2

2017 · External reference

Evaluating Psoriasis With Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

10.1016/j.jaad.2004.04.012 · 2004 · External reference

Comparison of Three Methods for Measuring Psoriasis Severity in Clinical Studies (Part 1 of 2): Change During Therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment

10.1111/jdv.13132 · 2015 · External reference

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

10.1177/24755303231155118 · 2023 · External reference

10.1002/jvc2.92

10.1002/jvc2.92 · External reference

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

10.1177/12034754231191509 · 2023 · External reference

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

10.1177/12034754231191509 · 2023 · External reference

User's Guide to Correlation Coefficients

10.1016/j.tjem.2018.08.001 · 2018 · External reference

Making Sense of Cronbach's Alpha

10.5116/ijme.4dfb.8dfd · 2011 · External reference

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why Do Both? A Systematic Analysis of Randomized Controlled Trials of Biologic Agents for Moderate to Severe Plaque Psoriasis

10.1016/j.jaad.2011.01.022 · 2012 · External reference

PGAxBSA Composite Versus PASI: Comparison Across Disease Severities and as Therapeutic Response Measure for Cal/BD Foam in Plaque Psoriasis

10.1016/j.jaad.2020.02.077 · 2020 · External reference